Studies published over the last five years have shown that MAP4K4 plays a role in the initiation and progression of cancer, primarily by activating intracellular proliferative signaling (such as the JNK and MLK3 pathways), impairing cytoskeleton function, and reducing anti-tumor immune responses. Here, MAP3K11 is linked to cancer.